Zynex Medical Chief Operating Officer Anna Lucsok joined Steve Darling from Proactive to discuss the company's commitment to non-invasive and non-opioid pain management solutions. Zynex is renowned for its flagship product, the NexWave, a multimodality electrotherapy device that has shown to reduce patient pain by 60% and medication use by 50%, according to patient surveys.
Lucsok highlighted the company’s direct-to-doctor marketing strategy, supported by a robust and expanding sales team of 350 representatives, with plans to grow to 800 in the coming years. Zynex’s efforts primarily target the U.S. market, where the demand for opioid alternatives remains high, though global expansion is envisioned within the next 3–5 years.
"We are seeing strong support from insurance companies and physicians for our NexWave device as they seek effective alternatives to opioids," Lucsok said. The company recently achieved a milestone of treating one million patients, underscoring its leadership in pain management. Zynex is poised to make a significant impact in combating the opioid crisis while providing patients with effective, accessible solutions.